Eton Pharma Jumps 20% Premarket as Q3 Revenue Triples and Full-Year Guidance Raised to $175M+
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton reported Q3 revenue of $57.9M, up about 158% year-over-year and $15.7M above consensus, driven by record patient counts on Increlex and Hemangeol. Non-GAAP EPS came in at $0.50 versus $0.04 a year ago, beating by $0.13, and adjusted EBITDA hit $28.5M with a 49% margin versus 13% last year. The company raised full-year revenue guidance to more than $175M from more than $145M and adjusted EBITDA margin to at least 40% from at least 35%. Shares rose more than 20% in premarket trading on the back of the beat and hike. This follows the Q3 8-K and 10-Q filed last night, which confirmed $57.9M in product sales and $49.9M of nine-month operating cash flow.
At the time of this announcement, ETON was trading at $58.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.27 to $66.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.